Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia.

Trial Profile

Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Perifosine (Primary)
  • Indications Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Chronic lymphocytic leukaemia; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 16 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Planned end date changed from 1 Nov 2008 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 08 Jun 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top